- Home
- SXC vs TRDA Comparison
SXC vs TRDA Comparison
Compare SXC & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- TRDA
- Stock Information
- Founded
- SXC 1960
- TRDA 2016
- Country
- SXC United States
- TRDA United States
- Employees
- SXC N/A
- TRDA N/A
- Industry
- SXC Steel/Iron Ore
- TRDA Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- TRDA Health Care
- Exchange
- SXC Nasdaq
- TRDA Nasdaq
- Market Cap
- SXC 722.8M
- TRDA 609.7M
- IPO Year
- SXC N/A
- TRDA 2021
- Fundamental
- Price
- SXC $12.63
- TRDA $18.05
- Analyst Decision
- SXC Strong Buy
- TRDA Strong Buy
- Analyst Count
- SXC 1
- TRDA 3
- Target Price
- SXC $13.00
- TRDA $23.33
- AVG Volume (30 Days)
- SXC 907.2K
- TRDA 132.6K
- Earning Date
- SXC 10-31-2024
- TRDA 11-05-2024
- Dividend Yield
- SXC 3.77%
- TRDA N/A
- EPS Growth
- SXC 55.48
- TRDA N/A
- EPS
- SXC 1.01
- TRDA 1.55
- Revenue
- SXC $1,970,000,000.00
- TRDA $215,232,000.00
- Revenue This Year
- SXC N/A
- TRDA $47.63
- Revenue Next Year
- SXC N/A
- TRDA N/A
- P/E Ratio
- SXC $12.42
- TRDA $11.77
- Revenue Growth
- SXC N/A
- TRDA 146.92
- 52 Week Low
- SXC $7.47
- TRDA $10.95
- 52 Week High
- SXC $12.81
- TRDA $20.49
- Technical
- Relative Strength Index (RSI)
- SXC 78.64
- TRDA 50.91
- Support Level
- SXC $12.29
- TRDA $17.09
- Resistance Level
- SXC $12.71
- TRDA $20.49
- Average True Range (ATR)
- SXC 0.42
- TRDA 0.96
- MACD
- SXC 0.03
- TRDA -0.20
- Stochastic Oscillator
- SXC 93.75
- TRDA 28.24
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.